Study of the Prediction System for Clinical Response to M-VAC Neoadjuvant Chemotherapy for Bladder Cancer

Abstract

Neoadjuvant chemotherapy for invasive bladder cancer, involving a regimen of M-VAC, can manage micrometastasis and improve the prognosis. However, some patients suffer from severe adverse drug reactions without any effect, and no method yet exists for predicting the response of an individual patient to chemotherapy. Our purpose in this study is to establish a method for predicting the response to the M-VAC therapy. We analyzed gene-expression profiles of biopsy materials from 40 invasive bladder cancers using a cDNA microarray consisting of 27 648 genes, after populations of cancer cells had been purified by laser-microbeam microdissection. We identified 14 predictive genes that were expressed differently between nine responder and nine non-responder tumors and devised a prediction-scoring system that clearly separated the responder group from the non-responder group. This system accurately predicted the clinical response for 19 of the 22 additional test cases. The group of patients with positive predictive scores had significantly longer survival times than that with negative scores. As real-time RT-PCR data were highly concordant with the cDNA microarray data for those 14 genes, we developed a quantitative RT-PCR-based prediction system that could be feasible for routine clinical use. Taken together, our ­results suggest that the sensitivity of an invasive bladder cancer to the M-VAC neoadjuvant chemotherapy can be predicted by expression patterns in this set of genes, a step toward achievement of “personalized therapy” for treatment of this disease.

Key words

bladder cancer - chemotherapy - cisplatin

References

• 1 Rosenberg J E, Carroll P R, Small E J. Update on chemotherapy for advanced bladder cancer.  J Urol. 2005;  174 14-20
• 2 Fagg S L, Dawson-Edwards P, Hughes M A et al. Cis-diamminedichloroplatinum (DDP) as initial treatment of invasive bladder cancer.  Br J Urol. 1984;  56 296-300
• 3 Pectasides D, Pectasides M, Nikolaou M. Adjuvant and neoadjuvant chemotherapy in muscle invasive bladder cancer: literature review.  Eur Urol. 2005;  48 60-68
• 4 Grossman H B, Natale R B, Tangen C M et al. Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer.  N Engl J Med. 2003;  349 859-866
• 5 Splinter T A, Scher H I, Denis L et al. The prognostic value of the pathological response to combination chemotherapy before cystectomy in ­patients with invasive bladder cancer. European Organization for ­Research on Treatment of Cancer – Genitourinary Group.  J Urol. 1992;  147 606-608
• 6 Okutsu J, Tsunoda T, Kaneta Y et al. Prediction of chemosensitivity for patients with acute myeloid leukemia, according to expression levels of 28 genes selected by genome-wide complementary DNA microarray analysis.  Mol Cancer Ther. 2002;  1 1035-1042
• 7 Kaneta Y, Kagami Y, Katagiri T et al. Prediction of sensitivity to STI571 among chronic myeloid leukemia patients by genome-wide cDNA micro­array analysis.  Jpn J Cancer Res. 2002;  93 849-856
• 8 Takata R, Katagiri T, Kanehira M et al. Predicting response to methotrexate, vinblastine, doxorubicin, and cisplatin neoadjuvant chemotherapy for bladder cancers through genome-wide gene expression profiling.  Clin Cancer Res. 2005;  11 2625-2636
• 9 Okabe H, Satoh S, Kato T et al. Genome-wide analysis of gene expression in human hepatocellular carcinomas using cDNA microarray: identification of genes involved in viral carcinogenesis and tumor progression.  Cancer Res. 2001;  61 2129-2137
• 10 Ono K, Tanaka T, Tsunoda T et al. Identification by cDNA microarray of genes involved in ovarian carcinogenesis.  Cancer Res. 2000;  60 5007-5011
• 11 Takata R, Katagiri T, Kanehira M et al. Validation study of the prediction system for clinical response of M-VAC neoadjuvant chemotherapy.  Cancer Sci. 2007;  98 113-117
• 12 Esrig D, Elmajian D, Groshen S et al. Accumulation of nuclear p53 and tumor progression in bladder cancer.  N Engl J Med. 1994;  331 1259-1264
• 13 Cote R J, Dunn M D, Chatterjee S J et al. Elevated and absent pRb expression is associated with bladder cancer progression and has cooperative effects with p53.  Cancer Res. 1998;  58 1090-1094
• 14 Zhou Z, Zwelling L A, Kawakami Y et al. Adenovirus-mediated human topoisomerase II alpha gene transfer increases the sensitivity of etoposide-resistant human breast cancer cells.  Cancer Res. 1999;  59 4618-4624
• 15 Topcu Z. DNA topoisomerases as targets for anticancer drugs.  J Clin Pharm Ther. 2001;  26 405-416